Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K. Kampen KR, et al. Leukemia. 2019 Feb;33(2):319-332. doi: 10.1038/s41375-018-0176-z. Epub 2018 Jun 21. Leukemia. 2019. PMID: 29930300 Free PMC article.
The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K. Girardi T, et al. Among authors: kampen kr. Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24. Leukemia. 2018. PMID: 28744013 Free PMC article.
VEGFC Antibody Therapy Drives Differentiation of AML.
Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM. Kampen KR, et al. Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5. Cancer Res. 2018. PMID: 30185550
Rise of the specialized onco-ribosomes.
Kampen KR, Sulima SO, De Keersmaecker K. Kampen KR, et al. Oncotarget. 2018 Oct 16;9(81):35205-35206. doi: 10.18632/oncotarget.26231. eCollection 2018 Oct 16. Oncotarget. 2018. PMID: 30443288 Free PMC article. No abstract available.
Ribosomal Lesions Promote Oncogenic Mutagenesis.
Sulima SO, Kampen KR, Vereecke S, Pepe D, Fancello L, Verbeeck J, Dinman JD, De Keersmaecker K. Sulima SO, et al. Among authors: kampen kr. Cancer Res. 2019 Jan 15;79(2):320-327. doi: 10.1158/0008-5472.CAN-18-1987. Epub 2018 Nov 27. Cancer Res. 2019. PMID: 30482776 Free PMC article.
Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Fancello L, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K. Kampen KR, et al. Leukemia. 2019 Apr;33(4):1055-1062. doi: 10.1038/s41375-019-0424-x. Leukemia. 2019. PMID: 30850735 Free PMC article.
Cancer Biogenesis in Ribosomopathies.
Sulima SO, Kampen KR, De Keersmaecker K. Sulima SO, et al. Among authors: kampen kr. Cells. 2019 Mar 11;8(3):229. doi: 10.3390/cells8030229. Cells. 2019. PMID: 30862070 Free PMC article. Review.
104 results